# Peptide Therapy Marketing Compliance: BPC-157, Ipamorelin, and the FDA Schedule Changes That Shifted Everything Peptide therapy marketing - BPC-157, Ipamorelin, TB-500, and adjacent compounds - faces a specifically shifting regulatory landscape. Here's what the FDA schedule changes mean for clinic marketing and how to lower your risk. By RegenCompliance Editorial (FDA/FTC compliance desk). Published 2026-02-25. Reading time 10 minutes. Canonical page: https://regencompliance.ai/blog/peptide-therapy-marketing-compliance Peptide therapy marketing exploded in wellness and longevity clinics in the late 2010s and early 2020s. BPC-157, Ipamorelin, TB-500, Sermorelin, CJC-1295, PT-141, and others became fixtures in wellness clinic service menus. In 2023, the FDA restricted compounding of several commonly-marketed peptides. The regulatory landscape has shifted substantially, and peptide clinic marketing that hasn’t updated to reflect the current status is operating in a different regulatory environment than it started in. ## What changed at the FDA The FDA’s [503A compounding framework](https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws) evaluates specific substances for compounding eligibility. Several peptides commonly used in wellness practice - including [BPC-157](https://regencompliance.ai/blog/bpc-157-peptide-marketing-503a-pharmacy) - were placed on the Category 2 list (significant safety risks), effectively restricting 503A compounding. Other peptides remain available through various pathways but with specific restrictions. For clinics: marketing peptides that are no longer appropriately compoundable, or marketing peptide therapy in ways that don’t reflect the current regulatory status, creates both substantiation issues (claims the practice can’t substantiate) and potential misbranding issues (marketing products that can’t legally be provided in the way described). The FDA’s [compounding Q&A resource](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) provides further detail on current pathway requirements. This changes quickly Peptide regulatory status has been in flux. FDA Category 1/2/3 assignments, 503A vs 503B pathway questions, and specific compounding-pharmacy availability change. Marketing should reflect the current regulatory status, not the status that existed when the marketing was written 18 months ago. ## The specific problem patterns ### Pattern 1: Marketing restricted peptides as broadly available Non-compliant “BPC-157 - healing and recovery peptide now available at our clinic.” Compliant alternative “(If a peptide is no longer appropriately compoundable for your state/pharmacy situation, remove it from marketing. Marketing products that cannot legally be provided is a misrepresentation issue beyond the standard compliance concerns.)” Why: Marketing peptides whose compounding status has been restricted creates a false impression that the product is readily available through standard channels. ### Pattern 2: Disease-specific outcome claims Non-compliant “BPC-157 heals leaky gut, tendonitis, and accelerates injury recovery.” Compliant alternative “Our practice offers a range of peptide therapy options for appropriate candidates with specific clinical concerns; the specific peptides, their current regulatory status, and candidacy are discussed at consultation.” Why: Disease and condition-specific treatment claims on peptides trigger FDA drug-claim rules regardless of the compounding-pharmacy status. ### Pattern 3: Performance and body composition claims Non-compliant “Ipamorelin and CJC-1295 - build lean muscle, lose fat, improve recovery.” Compliant alternative “Growth hormone-releasing peptides are one option in our comprehensive approach to specific clinical goals; we discuss candidacy and current options at consultation.” Why: Performance claims need substantiation; peptide-specific performance claims typically cannot meet the FTC evidence standard. ### Pattern 4: Anti-aging and longevity claims Non-compliant “Peptide therapy - turn back the clock and extend your lifespan.” Compliant alternative “Peptides are a broad category of signaling molecules involved in various biological processes. Research on specific peptides continues; our practice offers peptide options for clinically appropriate candidates.” Why: Anti-aging and longevity claims are FTC enforcement priorities. Biology-first framing is compliant; longevity outcome claims are not. ### Pattern 5: Research chemical sourcing Non-compliant “High-purity research-grade BPC-157 available for your wellness goals.” Compliant alternative “(Remove research-chemical sourcing from clinic marketing. Research-chemical framing is specifically concerning from both FDA and state controlled substance perspectives.)” Why: Research-chemical sourcing has specifically been cited in FDA enforcement action. Clinic marketing of research-chemical-sourced peptides is a high-risk pattern that involves more than just claim-level issues. ### Pattern 6: Injectable peptide marketing to at-home use Non-compliant “Weekly at-home peptide injections - convenient, effective, affordable.” Compliant alternative “Our in-clinic peptide protocol includes scheduled injections administered under clinical supervision; appropriate monitoring is part of our program.” Why: At-home injectable peptide marketing raises both supervision and safety considerations that regulators have cited. In-clinic framing is both clinically safer and compliance-safer. ## Compliant peptide therapy marketing framework ### Inventory current regulatory status Maintain a current inventory of which peptides you offer, under which pathway (503A compounded, 503B, other), and the current FDA status of each. Update this inventory as the regulatory landscape shifts. Marketing should match the current inventory. ### Generic category-first marketing “Peptide therapy options for appropriate candidates” as category-first marketing allows substitution as specific peptides change status. Marketing that depends on the availability of specific peptides by name creates maintenance overhead and regulatory risk when those peptides are restricted. ### Evidence-honest framing The clinical evidence for many peptides in specific indications is genuinely early-stage or non-existent. Honest framing acknowledges this: “Peptides as a broad category involve substantial ongoing research; specific peptides have varying evidence bases for specific applications.” ### Clinical-appropriateness forward Market the clinical evaluation process rather than the specific peptide products. “We evaluate patients for appropriateness for specific peptide therapy options based on clinical goals, medical history, and current regulatory availability” positions the practice appropriately. ## Specialty-specific considerations ### Sports medicine and recovery practices Marketing peptides for specific sports injuries or recovery outcomes combines peptide-specific issues with general sports-medicine substantiation issues; see our [sports medicine marketing guide](https://regencompliance.ai/blog/sports-medicine-marketing-compliance) for that framework. Use caution with specific-injury marketing. ### Longevity and wellness practices Longevity-framed practices face both peptide-specific issues and the general FTC focus on longevity claims. Combining peptides into longevity marketing packages can multiply compliance exposure. ### Hormone and TRT clinics Many hormone clinics incorporate growth hormone-releasing peptides (Sermorelin, Ipamorelin, CJC-1295). Marketing these alongside TRT creates combined compliance considerations from both specialty frameworks; see our [hormone therapy marketing guide](https://regencompliance.ai/blog/hormone-replacement-therapy-marketing-compliance) for that framework. ### Sexual wellness practices PT-141 (bremelanotide) and similar peptides in sexual wellness context face disease-specific claim issues (sexual dysfunction is a diagnosable condition). Vyleesi (bremelanotide) has FDA-approved specific indications that allow more specific marketing; compounded versions do not. ## Frequently asked questions ### Can I still market Sermorelin? Sermorelin has FDA-approved indications; specific compounding availability for clinic use depends on your pharmacy relationships and current regulatory status. Market specifically and keep the marketing current with your actual availability. ### What about international sourcing? International sourcing of peptides for US clinic use raises importation, customs, and FDA regulatory concerns beyond the standard marketing-compliance issues. This is a legal-counsel question, not a marketing question. ### Is telehealth peptide prescribing still viable? Depending on the specific peptide, state, and pharmacy relationship. Specific compounding-pharmacy availability and state prescribing rules apply. Marketing telehealth peptide services requires keeping pace with both the marketing-level compliance and the underlying regulatory viability of the service model. ### Are injectable peptides different from oral peptides? Regulatorily, both are subject to compounding-pharmacy rules and FDA claim rules. Practically, oral peptides have their own absorption and efficacy questions that affect substantiation of any efficacy claims made. ### What documentation should peptide clinics maintain? Current inventory of peptides offered and regulatory status, compounding-pharmacy documentation, substantiation files for any efficacy claims, patient intake and consent documentation, and regular review of regulatory status changes affecting current offerings. ### Should I drop aggressive peptide marketing? Many practices have substantially revised peptide marketing in response to the 2023 regulatory changes. Continuing aggressive pre-2023 marketing patterns is demonstrably higher-risk than it was two years ago. A marketing refresh that reflects current reality is both lower-risk and typically converts better with informed patients. Key Takeaways - FDA compounding category assignments in 2023 restricted availability of several commonly-marketed peptides including BPC-157. - Marketing that hasn't been updated to reflect current regulatory status creates both misrepresentation risk and substantiation issues. - Generic category-first marketing ('peptide therapy options') is more resilient than specific-peptide marketing that requires updating as availability shifts. - Research-chemical sourcing framing has been specifically cited in enforcement and should not appear in clinic marketing. - At-home injectable peptide marketing carries additional supervision concerns beyond in-clinic framing. --- RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt